Current Clinical Trials
Listed below are a few of our enrolling studies. If you do not see a condition that you are interested in please check back or contact us. We may have opportunities that are in the development phase or may consider your inquiry for future studies.
Vital Therapies, Inc. Alcohol-Induced Liver Decompensation Clinical Trial
If you know someone diagnosed with Alcohol-Induced Liver Decompensation (AILD) they may qualify for a study at the Medical College of Wisconsin/Froedtert Hospital. AILD includes those patients with Acute Alcohol Hepatitis, as well as patients with a chronic underlying liver disease with decompensation due to alcohol ingestion that is not due to Acute Alcoholic Hepatitis. This research being done to determine the safety and the effectiveness of the ELAD® System. The ELAD System is investigational and has not been approved by any regulatory agency. You can find more information at www.clinicaltrials.gov
To qualify one must be hospitalized and diagnosed with Alcohol-Induced Liver Decompensation, they cannot be eligible for liver transplant during hospitalization, and must be able to sign (or have a designated representative) sign the informed consent.
For more information please contact a study coordinator at 414-955-6987 or email@example.com
Gilead RAINIER IPF Clinical Trial
If you know someone diagnosed with idiopathic pulmonary fibrosis (IPF), they may qualify for a study at the Medical College of Wisconsin/Froedtert Hospital. The research is testing an investigational drug, Simtuzumab, compared to placebo (a safe, inactive substance) for benefits and safety. To qualify one must be 45-85 years of age, diagnosed with IPF and not listed as active on a lung transplant waiting list. Compensation for study related travel expenses may be provided. For more information please contact a study coordinator at 414-955-7030 or firstname.lastname@example.org
KaloBios KB001A-05 for Cystic Fibrosis
If you or someone you know has cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection, they may qualify for a study at the Medical College of Wisconsin/Froedtert Hospital. The research is designed to determine if multiple doses of KB001-A are safe and effective in people with CF and chronic Pa infection. Key criteria to qualify for this study include: ages 18 to 50 years, diagnosis of cystic fibrosis, respiratory tract culture with P. aeruginosa present in >50% of cultures within past 12 months, and a FEV1 between ≥40% and ≤80% predicted at screening. For more information please call Study Coordinator, Diana Rosik at 414-955-7085 or e-mail: email@example.com
You must also have the ability to come in for frequent visits and be available for weekly phone calls.
For more information please contact a Study Coordinator at 414-955-7030 or email firstname.lastname@example.org